scholarly journals Comparative Study on Data Sources of Detecting Adverse Drug Reactions

1996 ◽  
Vol 1 (2) ◽  
pp. 97-105
Author(s):  
Daisuke KOIDE ◽  
Shigekoto KAIHARA ◽  
Kazuhiko OHE ◽  
Chikuma HAMADA ◽  
Akifumi YAFUNE ◽  
...  
2010 ◽  
Vol 25 (12) ◽  
pp. 1876-1880 ◽  
Author(s):  
Santiago Perez-Lloret ◽  
Emmanuelle Bondon-Guitton ◽  
Olivier Rascol ◽  
Jean-Louis Montastruc ◽  

1992 ◽  
Vol 26 (9) ◽  
pp. 1149-1155 ◽  
Author(s):  
Michael B. Nichol ◽  
Lucy W. Michael

OBJECTIVE: This study evaluates the experience of 12 states that mandate that pharmacists provide consult services to patients and maintain drug profiles. DATA SOURCES: An analysis of each state's statutes and regulations was complemented by telephone interviews of state licensing board staff. RESULTS: Nine states specify the information to be provided during consultations, but only one (Florida) requires a comprehensive list of drug information, including adverse drug reactions, drug—drug interactions, directions for use, and necessary warnings. Eleven of the 12 states also require pharmacists to maintain patient drug profiles, but only 6 states specify the type of information to be included in profiles. State efforts to inform consumers about the pharmacist consultation requirement are limited, with only 7 states undertaking minimal promotional programs. The fact that no states reported any consumer consultation complaints or disciplinary actions against pharmacists for failure to consult illustrates the limited nature of mandatory consultation statutes and regulations. CONCLUSIONS: The wide variety of requirements demonstrates that these laws do not represent a uniform standard of practice. The lack of documented evidence regarding implementation invites questions regarding their usefulness and reinforces the need for enhanced monitoring activities.


2011 ◽  
Vol 21 (3) ◽  
pp. 285-288 ◽  
Author(s):  
Agnès Sommet ◽  
Genevieve Durrieu ◽  
Maryse Lapeyre-Mestre ◽  
Jean-Louis Montastruc ◽  

2002 ◽  
Vol 30 (3) ◽  
pp. 230-243 ◽  
Author(s):  
T Matsumoto ◽  
N Nagata ◽  
N Horikoshi ◽  
I Adachi ◽  
Y Ohashi ◽  
...  

The clinical usefulness of incadronate was compared with elcatonin in 26 patients with malignancy-associated hypercalcaemia. Data from 21 and 24 patients could be used to assess efficacy and safety, respectively. Eleven patients were given a single 10-mg intravenous infusion of incadronate and 10 received twice-daily intramuscular injections of 40 IU of elcatonin for 7 consecutive days. After treatment, corrected serum calcium levels decreased significantly in both groups. The anti-hypercalcaemic effect of elcatonin was characterized by its rapid onset, with serum calcium levels reduced 1 day after administration. In contrast, the anti-hypercalcaemic effect of incadronate was more sustained but only became apparent a few days after infusion. Evaluation of symptoms revealed significantly greater improvement rates in the incadronate group compared with the elcatonin group. Adverse drug reactions were observed in three patients in the incadronate group, i.e. mild and transient fever in two cases and exacerbation of disturbance of consciousness in one case. These findings suggest that incadronate produces more marked and sustained hypocalcaemic effects than elcatonin, and that co-administration of these two drugs may yield both rapid and sustained control of malignancy-associated hypercalcaemia.


1996 ◽  
Vol 41 (2) ◽  
pp. 166-168 ◽  
Author(s):  
J. P. LEMOZIT ◽  
G. PETIT DE LA RHODIERE ◽  
M. LAPEYRE-MESTRE ◽  
H. BAGHERI ◽  
J. L. MONTASTRUC

Sign in / Sign up

Export Citation Format

Share Document